98 related articles for article (PubMed ID: 17487750)
1. Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Patel S; Liu D; Caron P; Seiter K
Leuk Lymphoma; 2007 May; 48(5):1032-3. PubMed ID: 17487750
[No Abstract] [Full Text] [Related]
2. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
Bruckner HW; Hrehorovich VR; Sawhney HS; Meeus SI; Coopeman AM
J Chemother; 2006 Oct; 18(5):545-8. PubMed ID: 17127233
[TBL] [Abstract][Full Text] [Related]
4. Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Schwartzman AD; Sethi R; Smith R
Clin Colorectal Cancer; 2013 Jun; 12(2):136-9. PubMed ID: 23098664
[No Abstract] [Full Text] [Related]
5. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
6. What are the latest pharmacotherapy options for small bowel adenocarcinoma?
Ynson ML; Senatore F; Dasanu CA
Expert Opin Pharmacother; 2014 Apr; 15(6):745-8. PubMed ID: 24588646
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Sym SJ; Hong J; Park J; Cho EK; Lee JH; Park YH; Lee WK; Chung M; Kim HS; Park SH; Shin DB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):481-8. PubMed ID: 23192279
[TBL] [Abstract][Full Text] [Related]
8. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
[TBL] [Abstract][Full Text] [Related]
9. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
Des Guetz G; Bouillet T; Wind P; Morere JF
Gastroenterol Clin Biol; 2008 Oct; 32(10):875-6. PubMed ID: 18487031
[No Abstract] [Full Text] [Related]
11. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
13. [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
Sugae T; Yaguchi T; Kajikawa M; Nakayama S; Takase T; Inokawa Y; Tsushima Y; Watanabe T; Harada A
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1969-71. PubMed ID: 19011354
[TBL] [Abstract][Full Text] [Related]
14. A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
Catania C; Pelosi G; Fazio N; Biffi R; Spitaleri G; Noberasco C; Zampino MG; Maggioni A; Trifirò G; Toffalorio F; Vigna PD; De Braud F; De Pas T
Acta Oncol; 2010; 49(1):120-1. PubMed ID: 20100147
[No Abstract] [Full Text] [Related]
15. [Irinotecan in colorectal cancer].
Pozzo C; Cassano A; Barone C
Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
[No Abstract] [Full Text] [Related]
16. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
[TBL] [Abstract][Full Text] [Related]
18. Early small bowel perforation due to aflibercept.
Moussallem T; Lim C; Osseis M; Esposito F; Lahat E; Fuentes L; Salloum C; Azoulay D
Drug Discov Ther; 2017 Nov; 11(5):291-292. PubMed ID: 29021501
[TBL] [Abstract][Full Text] [Related]
19. Small bowel adenocarcinoma metastatic to the ovaries in a 12-year-old girl.
Dunsmore KP; Lovell MA
J Pediatr Hematol Oncol; 1998; 20(5):498-501. PubMed ID: 9787329
[TBL] [Abstract][Full Text] [Related]
20. Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
Trikudanathan G; Dasanu CA
Expert Opin Pharmacother; 2010 Jul; 11(10):1695-704. PubMed ID: 20446863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
